When should prophylaxis therapy in inhibitor patients be considered?

G. Young, G. Auerswald, V. Jimenez-Yuste, B. A. Konkle, T. Lambert, M. Morfini, E. Santagostino, V. Blanchette

Research output: Contribution to journalArticlepeer-review


Summary. Currently, patients with severe haemophilia can expect to lead a relatively normal life including prevention of disabling arthropathy as a result of the development of factor replacement therapy and advances in the understanding of the use of such therapy given prophylactically. Unfortunately, a subset of patients develops neutralizing antibodies termed inhibitors rendering such therapy ineffective. These patients frequently develop recurrent joint bleeding resulting in arthropathy. Until recently, prophylactic therapy was not considered for patients with inhibitors because of the perceived lack of an effective therapeutic agent. However, an accumulation of case reports and a recent prospective study have suggested that prophylaxis with the currently available bypassing agents could be effective and appears to be safe in selected cases. This report will review the current data on prophylaxis with bypassing agents and suggest specific situations in which prophylaxis in inhibitor patients could be considered.

Original languageEnglish
Issue number5
Publication statusPublished - Sep 2011


  • APCC
  • Inhibitors
  • Prophylaxis
  • Recommendations
  • RFVIIa
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)


Dive into the research topics of 'When should prophylaxis therapy in inhibitor patients be considered?'. Together they form a unique fingerprint.

Cite this